Kilian Guse
Directeur Général chez GeneQuine Biotherapeutics GmbH
Profil
Kilian Guse has founded GeneQuine Biotherapeutics GmbH in 2012, where he currently holds the title of Chief Executive Officer.
Dr. Guse's former jobs include being a Principal at SillaJen Biotherapeutics, Inc. and Bayer Australia Ltd.
Dr. Guse's education history includes an undergraduate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main and a doctorate degree from the University of Helsinki.
Postes actifs de Kilian Guse
| Sociétés | Poste | Début |
|---|---|---|
GeneQuine Biotherapeutics GmbH
 GeneQuine Biotherapeutics GmbH Pharmaceuticals: MajorHealth Technology GeneQuine Biotherapeutics GmbH develops gene therapy drugs for the treatment of osteoarthritis. Its gene therapy is to introduce genetic material into the patient's own cells in the body. The firm's genetic material will make the cells to produce a therapeutic protein. The company was founded by Kilian Guse and Stanislav Plutizki in October 2012 and is headquartered in Hamburg, Germany. | Directeur Général | 01/10/2012 |
Anciens postes connus de Kilian Guse
| Sociétés | Poste | Fin |
|---|---|---|
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | - |
Bayer Australia Ltd.
 Bayer Australia Ltd. BiotechnologyHealth Technology Bayer Australia Ltd. supplies and markets products to industries and resellers. Products include plastics, healthcare and specialty chemicals. The company was founded in 1925 and is headquartered in Pymble, Australia. | Corporate Officer/Principal | - |
Formation de Kilian Guse
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Undergraduate Degree |
| University of Helsinki | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Bayer Australia Ltd.
Bayer Australia Ltd. BiotechnologyHealth Technology Bayer Australia Ltd. supplies and markets products to industries and resellers. Products include plastics, healthcare and specialty chemicals. The company was founded in 1925 and is headquartered in Pymble, Australia. | Health Technology |
GeneQuine Biotherapeutics GmbH
GeneQuine Biotherapeutics GmbH Pharmaceuticals: MajorHealth Technology GeneQuine Biotherapeutics GmbH develops gene therapy drugs for the treatment of osteoarthritis. Its gene therapy is to introduce genetic material into the patient's own cells in the body. The firm's genetic material will make the cells to produce a therapeutic protein. The company was founded by Kilian Guse and Stanislav Plutizki in October 2012 and is headquartered in Hamburg, Germany. | Health Technology |
